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ReviewAbstract Imidazo[2,1-b][1,3,4]thiadiazole heterocycle was discovered during the 1950s. Since then,
many newer derivatives are being developed and evaluated for their biological proﬁles. The deriv-
atives of imidazo[2,1-b][1,3,4]thiadiazoles are widely explored for their biological potential viz. anti-
microbial, antifungal, anticancer, anticonvulsant, analgesic, antiinﬂammatory, anesthetic, and
diuretic. They are also reported as potential enzyme inhibitors of cyclooxygenase, Jun kinase, car-
bonic anhydrase demonstrating their possible signiﬁcance in target oriented drug design and discov-
ery. The present review highlights the last six decades of research on biological activities of the
imidazo[2,1-b][1,3,4]thiadiazoles.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The bridgehead nitrogen atom heterocycle, imidazo[2,1-
b][1,3,4]thiadiazole 1 consisting of four heteroatoms and two
condensed heterocycles with different p-conjugations was ﬁrstdiscovered in the early ﬁfties of nineteenth century (Matsukawa,
1952). This heterocycle is an isoster of biologically signiﬁcant
imidazo[1,3,4]thiazole, in which the 3-CH group of thiazole ring
is substituted by 3-N atom.
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During the past six decades, signiﬁcant development has
been observed in the ﬁeld of chemistry and biology of imi-
dazo[2,1-b][1,3,4]thiadiazoles. The synthesis and biological
activities of numerous imidazo[2,1-b][1,3,4]thiadiazoles
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Scheme 2 Synthesis of imidazo[2,1-b][1,3,4]thiadiazoles from
1-amino-2-(methyl)thio-4-substituted-imidazoles VIII.
S464 B.A. Bhongade et al.possessing a variety of substitutions at C-2, C-5 and/or C-6
positions of the general structures 2–4 have been reported
widely in the literature.
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Most of the synthesized derivatives are reported to exhibit
diversiﬁed biological activities as well as inhibition of some
speciﬁc enzymes. The biological activities includes antibacte-
rial, antifungal, leishmanicidal, herbicidal, antitubercular,
anticancer, anthelmintic, anticonvulsant, analgesic, antiinﬂam-
matory, antipyretic, local anesthetic, cardiotonic and diuretic.
The recent review provides a comphrensive summary on the
chemistry of imidazo[2,1-b][1,3,4]thiadiazole highlighting an
overview on the methods of synthesis, spectral studies, physi-
cochemical properties, reactivity as well as ring fused imi-
dazo[2,1-b][1,3,4]thiadiazoles (Khazi et al., 2011). To the best
of our knowledge, this is the ﬁrst comphrensive review of bio-
logical proﬁles of the imidazo[2,1-b][1,3,4]thiadiazole heterocy-
cle which includes literature published during the last 60 years.
We believe that the present review will provide medicinal and
bioorganic chemists a collective insights into the biological
proﬁles of imidazo[2,1-b][1,3,4]thiadiazole derivatives, thus
helping them adopt a more focused and speedy target oriented
drug discovery process.
2. General methods of synthesis
The method of synthesis and the chemistry have been reviewed
in detail (Khazi et al., 2011), highlighting the overview of
general methods of the synthesis of imidazo[2,1-b][1,3,4]
thiadiazoles.
In general, the substituted imidazo[2,1-b][1,3,4]thiadiazoles
3 are prepared either by condensation of 2-amino-5-substituted
[1,3,4]thiadiazoles I with various reagents viz. a-haloketones II,
acetophenones III, diethylchloroacetal IV, chloroacetyl chlo-
ride V, haloacetic acid VI and dimethyl formamide dimethyl
acetal VII (Scheme 1) or by the reaction of 1-amino-2-N
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Scheme 1 Synthesis of imidazo[2,1-b][1,3,4]thiadiazoles 3 from
2-amino-5-substituted[1,3,4]thiadiazoles I (X = Cl/Br).(methyl)thio-4-substituted-imidazoles VIII with chloroacetyl
chloride (Scheme 2).
The most versatile method of synthesizing 2,6-disubsti-
tuted-imidazo[2,1-b][1,3,4]thiadiazoles 3 involves reﬂuxing
2-amino-5-substituted-[1,3,4]thiadiazoles I with appropriate
a-haloketones II (Matsukawa, 1952). This reaction was
also achieved in the presence of one of the solvents:
acetone, DMF, ethanol, methanol, propanol and water.
Ethanol is the widely employed solvent while the use of
other solvents effected the overall completion of reaction
in many cases.
Condensation with acetophenones III with I resulted in the
formation of compound 3 in the presence of either N-bromo-
succininimide or [hydroxyl(tosyloxy)iodo]benzene (Jag et al.,
1989a, 1993). Synthesis of compound 3 was achieved via
Schiff base intermediate and its intramolecular cyclization by
the reaction of I with diethylchloroacetal IV and triethylamine
in acetonitrile (Scozzafava and Supuran, 1997). Reaction of
chloroacetyl chloride V with I afforded the imidazo[2,1-
b][1,3,4]thiadiazol-6-ones via 2-chloroacetamido intermediate
(Cativiela et al., 1989). Similarly, the reaction of haloacetic
acid VI with I yielded 2-imino[1,3,4]thiadiazol-3-yl]acetic acid
intermediates which underwent intramolecular cyclization to
yield corresponding 2-substituted-6-haloimidazo[2,1-b][1,3,4]
thiadiazoles (Ivashchenko et al., 1990).
Synthesis of 2,5- and 2,6-disubstituted-imidazo
[2,1-b][1,3,4] thiadiazoles (IX and 3) was achieved by the
reaction of 1-amino-2-(methyl)thio-4-substituted-imidazoles
VIII in the presence of N,N-dimethyl formamide dimethyl
acetal following a series of reactions (Fajgelj et al., 1986)
(Scheme 2).
Synthesis of 2,5,6-trisubstituted-imidazo[2,1-b][1,3,4]thi-
adiazoles 4 was achieved in a one step reaction by the conden-
sation of 2-amino-5-substituted-[1,3,4]thiadiazoles I with
substituted haloketones X such as 2-chloroacetoacetate ethyl
ester (Ban, 1954), 2-bromo-1-aryl-propan-1-ones (Pyl, 1963),
2-chloroacetoacetate Abignente et al. (1985), 2-bromo-1-phe-N
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Scheme 3 Synthesis of 2,5,6-trisubstituted-imidazo[2,1-b][1,3,4]
thiadiazoles from 2-amino-5-(un)substituted [1,3,4]thiadiazoles I
(X = Cl/Br, R5, R6 = alkyl, (hetero)aryl).
NS
N
N
R6
+
N
S
NH
NH
Solvent,
R2
R2
N
S
N
NH
R6
O
R2
HBr
H
R5
OH
N
S
N
N
R6R2
,-H2O
Ia
HBr
X
R6O
R5N
S
N
NH2R2
R5
I
R5
N
S
N
N
R6R2
base
R5
XII
XIIIXIV3/4
II/X
Scheme 4 Reaction mechanism of formation of imidazo[2,1-b][1,3,4]thiadiazoles.
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mo-1,2-disubstituted-1-ethanones (Gadad et al., 2008; Paul,
1977; Pentimalli et al., 1975) (Scheme 3).
Alternatively, compound 4 was synthesized from 2,6-disub-
stituted-imidazo[2,1-b][1,3,4]thiadiazole 3 by different chemi-
cal reactions: electrophilic substitution, nucleophilic
displacement, nitration, bromination, reduction, Vilsmeier–
Haack formylation, Mannich and Schiff bases formation (for
details refer Khazi et al., 2011).
The widely accepted mechanism of reaction for the for-
mation of imidazo[2,1-b][1,3,4]thiadiazoles 3/4 from the
condensation of 2-amino-5-substituted-[1,3,4]thiadiazole I
with substituted haloketones II/X is depicted in Scheme 4.
The nucleophile attack on N-3 nitrogen of iminothiadiazole
Ia results in a stable intermediate 2-imino-2,3-dihydro-
[1,3,4]thiadiazole halides XII which can be isolated. The
intermediate XII further undergoes intramolecular cyclode-
hydration via XIII to afford halide salts XIV of imi-
dazo[2,1-b][1,3,4]thiadiazoles 3/4 which upon neutralization
yield free bases 3/4.
3. Biological activity
Imidazo[2,1-b][1,3,4]thiadiazole derivatives are evaluated for
the various biological activities and some of them have dis-
played signiﬁcant activity.
3.1. Antibacterial and antifungal activity
Most of the research in the ﬁeld of imidazo[2,1-b][1,3,4]thi-
adiazoles is focused on their in vitro evaluation as antibacterial
agents against several Gram positive and Gram negative mi-
crobes and as antifungal agents.
Mazzone et al. (1984) screened 2,6-diaryl-imi-
dazo[2,1-b] [1,3,4]thiadiazoles 5 against the bacterial strains:
Staphylococcus aureus (S. aureus), Escherichia coli (E. coli)
and fungal strains:Candida albicans (C. albicans),Candida trop-
icatis (C. tropicatis) and Cryptococcus neoformans (C. neofor-
mans). The minimal inhibitory concentration (MIC) against
bacterial strains (100 lg/mL) and against fungal strains (3.12–
25 lg/mL) indicated that these compounds were relatively poor
bactericidal and better fungicidal agents. The most active com-
pound (5: R2 = 3,4-(O–CH2–O)–C6H3; R6 = 4-Br–C6H4)
exhibited MICs of 6.25, 12.5 and 6.25 lg/mL againstC. albicans, C. tropicatis and C. neoformans fungal strains,
respectively.
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R2= 3,4,5-OMe3-C6H2; R6= C6H5, 2-NO2-C6H4, 4-NO2-C6H4, 4-Br-C6H4;      
R2= 3,4(O-CH2-O)-C6H3; R6= C6H5, 2-NO2-C6H4, 4-NO2-C6H;   
R2= 3,5-OMe2,4-OEt-C6H2; R6= C6H5, 2-NO2-C6H4, 4-NO2-C6H4, 4-Br-C6H4; 4-Cl-C6H4
Chaturvedi et al. (1989) evaluated 2-substituted phenoxy
methylimidazo[2,1-b][1,3,4]thiadiazole-6-ones 6 for antibacte-
rial activity against S. aureus and Bacillus subtilis (B. subtilis)
as well as for antifungal activity against A. niger and Helmin-
thosporium oryzae. These compounds were inactive against the
tested antibacterial and antifungal strains at 1000 mg/L con-
centrations.
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Moderate antibacterial and antifungal activity againstE. coli
and C. albicans, respectively was reported for 2-(thio/oxo-
methyl benzimidazolo)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles
7,8 Ashour et al. (1990, 1991).
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X= O;  R= CH3, CH2C6H5;    R6= C6H5, 4-Br-C6H4; 4-Cl-C6H4; 4-Me-C6H4; 4-OMe-C6H4.
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Gadad et al. (1992) reported 2-alkyl-6-arylimidazo[2,1-b]
[1,3,4]thiadiazoles 9 and their 5-bromo derivatives as insignif-
icant antibacterial agents against E. coli, S. aureus and anti-
fungal agents against C. albicans and A. niger when tested at
75 and 200 lg/disk in DMF compared to salicylic acid as stan-
dard drug.
S466 B.A. Bhongade et al.N
S
N
N
R6R2
9
R2= CH3(CH2)6, CH3(CH2)10, CH3(CH2)7-CH=CH(CH2)7, cyclohexyl; R6= C6H5; R5= H.
R2= CH3(CH2)6, CH3(CH2)10, CH3(CH2)7-CH=CH(CH2)7, cyclohexyl; R6= 4-Cl-C6H4; R5= H.
R2= CH3(CH2)6, CH3(CH2)7-CH=CH(CH2)7, cyclohexyl; R6= 4-CH3-C6H4; R5= H.
R2= CH3(CH2)6, CH3(CH2)10, CH3(CH2)7-CH=CH(CH2)7, cyclohexyl; R6= 4-OCH3-C6H4; R5= H.
R2= CH3(CH2)6, CH3(CH2)10, cyclohexyl; R6= C6H5; R5= Br.
R2= CH3(CH2)6, CH3(CH2)10, cyclohexyl; R6= 4-Cl-C6H4; R5= Br.
R2= CH3(CH2)6, CH3(CH2)10, cyclohexyl; R6= 4-CH3-C6H4; R5= Br.
R5
Gadaginamath et al. (1999) reported moderate activity
of 2-phenyl-6-(1-substituted-indol-3-yl)-imidazo[2,1-b][1,3,4]
thiadiazoles 10 against E. coli, B. cirroﬂagellous bacterial
strains and A. niger, C. albicans fungal strains using griseoful-
vin as standard drug. These compounds exhibited relatively
better antifungal activity against A. niger compared to
C. albicans.
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Gadad et al. (2000) evaluated antibacterial activity of vari-
ous 6-arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide/N-
(dimethylamino)sulfonamides 11 and their 5-thiocyanato 12
and 5-guanylhydrozone 13 derivatives against E. coli, S. aur-
eus, Salmonella typhi (S. typhi), P. aeruginosa and Pneumococci
by the cup-plate method using Muller–Hinton agar medium. 6-
Arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamides 11 were
inactive against S. aureus and P. aeruginosa, however they
were moderately active against E. coli, S. typhi and Pneumo-
cocci, while their 5-thiocyanato 12 and 5-guanylhydrazone 13
derivatives were signiﬁcantly active against E. coli and S. aur-
eus. Among these, the most active compounds (12: R6 = 4-Br–
C6H4, 4-Cl–C6H4, 4-NO2–C6H4; 13: R6 = 4-Br–C6H4, 4-Cl–
C6H4) were reported to be equipotent in activity compared
to sulfamethoxazole against E. coli and S. aureus. The presence
of thiocyanato and guanylhydrozone groups at 5-position
overall enhanced the antibacterial spectrum of these series of
compounds. However the compounds were reported to be less
active than norﬂoxacin.
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Zhang et al. (2002a,b) reported signiﬁcant antibacterial activ-
ity of 2-(1-aryl-5-methyl-1,2,3-triazol-4-yl)-6-phenylimidazo
[2,1-b][1,3,4]thiadiazoles 14 and 2-alkyl/aryl-6-phenylimi-
dazo[2,1-b][1,3,4]thiadiazoles 15 against E. coli, P. aeruginosa,
B. subtilis and S. aureus using chloromyctin as standard drug.N
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o-ClC6H4,
p-ClC6H4,
p-BrC6H4,
p-CH3C6H4,
C6H5.
R2=
Kolavi et al. (2006) evaluated 2,6-disubstituted and 2,5,
6-trisubstituted derivatives of imidazo[2,1-b][1,3,4]thiadiazoles
16 for their antibacterial properties against Bacillus cirrhosis
(B. cirrhosis), E. coli and antifungal activity against A. niger,
Penicillium wortmannii (P. wortmannii) at 25–100 lg/mL using
norﬂoxacin and griseofulvin as standard drugs. Mannich bases
at C-5 with C-2 cyclohexyl and 2-thienyl with phenyl substitu-
tion at C-6 showed relatively more antimicrobial inhibition.
Pyrrolidine derivative (16: 2-(2-thienyl)-5-pyrrolidin-1-yl-
methyl) exhibited a complete inhibition of B. cirrhosis at
100 lg/mL,whereas, C-2 cyclohexyl derivatives withC-6 phenyl
substitution showed 90–100% inhibition against E. coli. Over-
all, 5-substituted analogs of 2-(2-furyl)-6-phenylimidazo[2,1-b]
[1,3,4]thiadiazoles exhibited better activity against E. coli.
A similar trend was observed with antifungal activity.
Mannich bases displayed better antifungal activity where
cyclohexyl derivative (16:2-cyclohexyl-6-phenyl-5-(pyrrolidin-
1-ylmethyl)-imidazo[2,1-b][1,3,4]thiadiazole) showed 100%
inhibition against A. niger and P. wortmannii at 100 lg/mL.
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R2= R5= R6=C6H11,
2-furyl,
2-thienyl
H,
CHO,
CH2OH,
CH=N-OH,
CN,
3-phenyl-1,3-thiazolidin-2-yl-4-one,
morpholin-4-ylmethyl,
piperidine-1-ylmethyl,
pyrrolidin-1-ylmethyl,
C6H5,
4-Br-C6H4.
Hegde et al. (2006) have studied antibacterial activity
against B. cirrhosis, E. coli and antifungal activity against A.
niger, P. wortmannii of 5-cyclicaminomethyl Mannich bases
and 2-benzothiozolyl derivatives of 2-propyl/cyclohexyl/(2-thi-
enyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles 17 at 100 lg/mL
by the cup plate method. Mannich bases exhibited relatively
better antifungal activity.
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R'4= H, Br, Cl, CH3, OCH3
R2= C6H11, 2-furyl, propyl, 2-thienyl
R1= 4-morpholinyl, 1-piperidinyl, 1-pyrrolidinyl
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fungal activity of 2-methyl-6-[2-(5-nitrofuryl)]-imidazo[2,1-
b][1,3,4]thiadiazole 18 against Fusarium roseum at a dilution
of 1:1000.
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Srivastava et al. (1991) reported 81–89% and 85–92% inhi-
bition at 1000 ppm concentration against A. niger and H.
oryzae, respectively by 2-(1-substituted phenoxy-ethyl)-6-ary-
limidazo[2,1-b][1,3,4]thiadiazoles 19.
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R= 4-Cl-3-CH3-C6H3,
4-(CH3)3-C6H4,
2,4-(CH3)2-C6H3
19
2-Phenyl-imidazo[2,1-b][1,3,4]thiadiazole-6-ones 20 exhib-
ited comparable fungitoxicity to that of mancozeb standard
drug against A. niger and F. oxysporium at a dilution of
1000 ppm (Yadav and Vaish, 1994). Antibacterial and anti-
fungal activity of imidazo[2,1-b][1,3,4]thiadiazoles 21 have also
been reported (Dehuri and Nayak, 1982).
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R2=
Jag et al. (1989a,b, 1993), Jag (1999, 2000), Jag and
Anupama (2000), Jag and Kumar (2002), Jag and Shikha
(2005) and Kumar et al. (2006) evaluated 2-alkyl/
(hetero)aryl-6-aryl imidazo[2,1-b][1,3,4]thiadiazoles 22 and
their 5-bromo derivatives for antibacterial and antifungal
properties against E. coli, S. aureus, P. aeruginosa and
C. albicans, respectively. Some of these compounds were
reported to be active against the tested microbes.
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R2= 4-Cl-C6H4; R6= C6H5, 4-Cl-C6H4, 4-Ph-C6H4.
R2= 2-CH3-C6H4; R6= C6H5, 4-Br-C6H4, 4-Cl-C6H4, 4-Ph-C6H4.
R2= 2,4-Cl2-C6H3: R6= C6H5.
R2= 2,4-Cl2-C6H3; R6= C6H5; R5= Br.
R2= 4-tBu-C6H4; R6= 4-Cl-C6H4.
R2= 4-tBu-C6H4; R6= 4-Cl-C6H4;R5= Br.
R2= 2-pyridyl; R6= C6H5, 4-Br-C6H4, 4-Cl-C6H4.
R2= 2-pyridyl; R6= C6H5, 4-Br-C6H4, 4-Cl-C6H4;R5= Br.
R2= 2-OH-C6H4; R6= C6H5, 4-Br-C6H4, 4-Cl-C6H4.
R2= 2-OH-C6H4; R6= C6H5, 4-Br-C6H4, 4-Cl-C6H4;R5= Br.
Andotra et al. (1993) investigated antibacterial activity
of 2-aryl-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazoles
23 and their 5-bromo and 5-nitro derivativesN
S
N
N
Br
R5R'2
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23Weuffen and Gruebner (1965) and Tattler (1966) studied
the bacteriostatic and fungistatic properties of 2-amino-6-ary-
limidazo[2,1-b][1,3,4]thiadiazoles. The compounds were inac-
tive against S. aureus, Enterococci, S. typhosa, E. coli,
Proteus mirabilis and P. aeruginosa.
Alegaon and Alagawadi (2011) reported moderate antibac-
terial against E. coli, P. aeruginosa, S. aureus and E. faecalis
and antifungal activity against C. albicans, A. ﬂavus, A. niger
and C. neoformans of 5-[methylene-2,4-dioxo/(4-oxo,2-thioxo)-
thiazolidin)-3-yl) acetic acid]-6-arylimidazo[2,1-b] [1,3,4]thiadiaz-
oles 24a. (Alagawadi and Alegaon, 2011) reported antibacterial
and antifungal activity of some 5-[(2-(3,4,5-trimethoxyphenyl)-
6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylidene]-1,
3-thiazolidine-2,4-dione 24b and N-[(dimethylamino)methyli-
dene]-5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-arylim-
idazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide28 inMueller–Hinton
broth and Sabouraud dextrose agar medium, respectively.
The compounds exhibited moderate antibacterial activity
against the Gram-positive S. aureus, E. faecalis, Gram-
negative E. coli, P. aeruginosa bacteria compared to ampicillin
and moderate antifungal activity against C. albicans, A. ﬂavus
and A. niger compared to ketoconazole.
N
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N
N
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N
S
OX
R5'
24
R2
X= O, S;
C6H5,
4-CH3-C6H5,
4-OCH3-C6H5,
4-NO2-C6H5,
4-Br-C6H5,
4-Cl-C6H5,
2,5-OCH3-C6H5
R=
24a:
R5'= CH2COOH
R2= 3,4,5-(OMe3)C6H2
X= O, S;
C6H5,
4-CH3-C6H5,
4-OCH3-C6H5,
4-NO2-C6H5,
4-Br-C6H5,
4-Cl-C6H5,
2,5-OCH3-C6H5
R=
24b:
R5'= H
R2= 3,4,5-(OMe3)C6H2
X= O, S;
C6H5,
4-CH3-C6H5,
4-OCH3-C6H5,
4-NO2-C6H5,
4-Br-C6H5,
4-Cl-C6H5,
2,5-OCH3-C6H5
R=
24C:
R5'= CH2COOH
R2= CF3
SO2NCHN(CH3)2
Dhepe et al. (2011) reported moderate antibacterial
activity against S. aureus and Klebsiella and antifungal activ-
ity against C. albicans of 2-((un)substituted benzoyl)-
6-(4(un)substituted) imidazo[2,1-b][1,3,4]thiadiazoles 25 using
the cup-plate method.
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R= Cl, NO2
R'4= Br, Cl, CH3, OCH3, NO2
Atta et al. (2011) reported comparatively more antibacterial
and antifungal activity of 6-aryl-2-(2-aryl-2H-1,2,3-triazo-4-yl)
imidazo[2,1-b][1,3,4]thiadiazoles 26 than imipenem and
co-trimoxazole, respectively, using the agar diffusion method
against E. coli, P. aeruginosa and C. albicans.
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R'4
N
N N
R
R5
R= H;         
R= Br;       
R= Cl;           
R= I;
R'4= H,Br,Cl;   
R'4= H,Br,Cl;     
R'4= H,Br;          
R'4= Cl;
R5= H,Br,I
R5= H,Br,I
R5= H,Br,I
R5= CHO
Recently Kaur et al. (2012) evaluated biphenyl imidazo[2,1-
b][1,3,4]thiadiazoles 27 for their antibacterial activity against
E. coli, P. aeruginosa, and B. subtilis and antifungal activity
against C. albicans, A. niger and S. cerevisiae using ampicillin
and amphotericin B as standard drugs. Compounds exhibited
signiﬁcant antibacterial and low antifungal activity compared
to standard drugs.
N
S N
27
R2 R6
R2=
R6=
4-C6H5,3-F-C6H4
C6H5,
4-Cl-C6H4,
4-F-C6H4,
2,4-Cl2-C6H3
4-NH2-C6H4,
2,4-(OH)2-C6H3,
4-Br-C6H4,
2-OH-C6H4,
Overall, the reported imidazo[2,1-b][1,3,4]thiadiazoles
exhibited low to moderate antibacterial and antifungal proper-
tites. It is observed that the alkyl/aryl substituents at C-2 and
C-6 positions of imidazo[2,1-b][1,3,4]thiadiazoles does not sig-
niﬁcantly inﬂuence the antimicrobial and antifungal proﬁles.
However, the C-5 substituents such as gunidino, thiocyanato
and formyl groups showed some inﬂuence on antibacterial
activities.
3.2. Antitubercular activity
Arya et al. (1972) reported antitubercular (antiTB) activity of
2-methyl-6-(5-nitro-2-thienyl)-imidazo[2,1-b] [1,3,4]thiadiazole
28 against Mycobacterium tuberculosis (M. tb.) H37Rv strain.
N
S
N
N
28
S NO2Gadad et al. (2004) have evaluated 6-aryl-2-sulfonamido/
N-(dimethylamino)-sulfonamido/triﬂuoromethyl-imidazo[2,1-
b][1,3,4]thiadiazoles and their 5-bromo/thiocyanato/guanylhy-
drozino derivatives against M. tb.H37Rv strain by radiometric
BACTEC and broth dilution assay (11: R6 = 4-OMe–C6H4;
3,4,5-OMe3–C6H2; 4-F–C6H4; 12,13: R6 = 4-Cl–C6H4; 4-F–
C6H4; 13: R5 = Br; R6 = 3,4,5-OMe3–C6H2 and 29). It was
found that 5-guanylhydrozino derivatives 13 exhibited 43–
58% inhibition at 6.25 lg/mL concentration. No signiﬁcant ef-
fect on antiTB activity was reported when 2-sulfonamido
group was replaced with the 2-triﬂuoromethyl group. The
compounds were reported to be less active than the standard
drug isoniazid.
N
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N
N
R6F3C
29
R6= 4-OCH3-C6H4,
4,5,6-(OCH3)3-C6H2,
4-NO2-C6H4,
4-F-C6H4,
4-Cl-C6H4,
4-Br-C6H4,
4-OH-C6H4,
4-CH3-C6H4,
2-furyl,
3-coumarinyl
Kolavi et al. (2006) reported antiTB activity of 2-cyclo-
hexyl/(2-furyl)/(2-thienyl)-6-phenyl/(4-bromophenyl)-5-substi-
tuted imidazo[2,1-b][1,3,4]thiadiazoles (16: R2 = C6H11, 2-furyl,
2-thienyl, R5 = H, CHO, CH2OH, R6 = C6H5, 4-Br–
C6H4; 16: R2 = C6H11, 2-furyl, 2-thienyl, R5 = CH‚NOH,
CN, 3-phenyl-1,3-thiazolidin-2-yl-4-one, R6 = C6H5) against
M. tb. H37Rv strain at 6.25 lg/mL concentration using
rifampicin as standard drug. The results of antiTb studies
indicated 5-carbaldehyde derivatives exhibited better activity
than 5-substituted aminomethyl/methanoyl/carbaldehyde
oxime/carbonitrile/(3-phenyl-1,3-thiazolidine-one) derivatives.
2-(2-Furyl)-6-phenyl-5-carbal-dehydeimidazo[2,1-b][1,3,4]
thiadiazole and (2-cyclohexyl-6-phenylimidazo[2,1-b][1,3,4]
thiadiazole-5-yl) methanol showed 100% inhibition at
6.25 lg/mL concentration. 2-Cyclohexyl, 2-furyl and 6-phe-
nyl groups contributed more to the antiTB activity. Over-
all 5-substituted derivatives exhibited moderate to good
antiTB activity while 5-unsubstituted derivatives did not
show any considerable activity. Similarly, Hegde et al.
(2006) reported antiTB activity of 5-cyclic aminomethyl
Mannich bases, carbaldehydes and 2-benzothiozolyl deriva-
tives of 2-propyl/ cyclohexyl/(2-thienyl)-6-aryl-imidazo[2,1-
b][1,3,4]thiadiazoles 17 against M. tb.H37Rv strain. The
compounds exhibited 34–99% inhibition at 6.25 lg/mL
concentration.
Moderate antiTB activity of 2-(triﬂuoromethyl)-6-arylim-
idazo[2,1-b][1,3,4]thiadiazole derivatives containing rhoda-
nine-3-acetic acid 24c against M. tb.H37Rv strain (MICs
in the range of 3.12–1.56 lg/ml) was reported (Alegaon
et al., 2012). Palkar et al. (2012) recently reported moderate
to low antiTB activity of some 2-substituted-5,6-diaryl-
substituted imidazo[2,1-b]-1,3,4-thiadiazoles 30 against
M. tb.H37Rv strain (MICs in the range of 1.25–10 lg/ml)
by the MABA method using isoniazid and gatiﬂoxacin as
standard drugs.
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H, 
OCH3
CF3, 
SO2NH2,
4-F-C6H4,
4-OCH3-C6H4
H, 
CH3, 
OCH3, 
SCH3,
R'4= R=R2=
3.3. Anticonvulsant activityAnticonvulsant activity of 6-alkyl/(hetero)arylimidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamides and their 2,5-alkyl deriva-
tives 31 has been studied (Barnish et al., 1980) in male mice
by the electroshock test method at a dose of 2.5, 6.25 and
16 mg/kg. Some of the compounds were reported to exhibit
oral anticonvulsant ED50 values greater than 4-[(4-methoxypi-
peridino)sulfonyl]-2-chloro-benzenesulfonamide, acetazola-
mide and methazolamide standard drugs. The most active
compound 6-tert-butylimidazo[2,1-b][1,3,4] thiadiazole-2-sul-
fonamide exhibited a oral ED50 value of 2.6 mg/kg.
N
S
N
N
R6
31
S
H2N
O
O
H, 
CH3, 
C2H5, 
(CH3)3C, 
C10H15,
-CH2(CH2)2CH2-,    
C6H5, 
2-OH-C6H4, 
4-OH-C6H4, 
4-CH3-C6H4,  
4-CH3O-C6H4, 
4-NHCOCH3-C6H4, 
2-C4H3S
R6=
Similarly, Khazi et al. (1996) reported signiﬁcant anticon-
vulsant activity of 6-(hetero)arylimidazo[2,1-b][1,3,4]thiadia-
zole-2-sulfonamides 32 using phenobarbitone sodium and
phenytoin sodium as standard drugs. 6-Aryl derivatives were
found to exhibit protection against pentylenetetrazole-induced
convulsions and maximum electroshock-induced seizures in al-
bino mice at the dose of 300 mg/kg b.w. and the degree of pro-
tection ranged 67–83% and 33–83%, respectively. However,
bromination at the C-5 position reduced activity (degree of
protection 67%).
N
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N
R6
32
H2NO2S
R5
R5=H; R6= 4-NO2-C6H4,  
4-C6H5-C6H4,  
3-coumarinyl, 
5-NO2-2-thienyl
R5=Br; R6= 3-coumarinyl
3.4. Antiinﬂammatory, analgesic and antipyretic activityAbignente et al. (1985) evaluated 6-carbamic acid/carbamic
acid methyl ester-2-ethyl and 6-carbamic acid-2,6-dimethylim-idazo[2,1-b][1,3,4]thiadiazoles 33 for their antiinﬂammatory,
analgesic, antipyretic and ulcerogenic activities using indo-
methacin as standard drug. The compounds showed weak
antiinﬂammatory activity on the carrageenin-induced rat paw
edema model and deﬁed inhibitory action on the release of
lysosomal enzymes in the pleurisy test. However, the com-
pounds exhibited analgesic activity in the acetic acid writhing
test and were completely devoid of analgesic activity in the
hot plate test and yeast-induced pyrexia..
N
S
N
N
R6R2
33
R2= H, CH3, C2H5
R6= COOC2H5, CH2COOC2H5
Superior analgesic activities of 6-(hetero)arylimidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamides 32 were compared to ace-
tylsalicylic acid (Khazi et al., 1996). These compounds showed
maximum analgesic effect 50–65% after 1 h interval in the rat
caudal immersion test.
Gadad et al. (2008) reported cyclooxygenase (COX) inhib-
itory and antiinﬂammatory activities of 2-triﬂuoromethyl/sul-
fonamido-5,6-diarylimidazo[2,1-b][1,3,4]thiadiazoles (30: R2
= CF3, SO2NH2; R
04 = H, F, CH3, OCH3, SCH3, SO2CH3;
R = H, OCH3). The compounds exhibited selective inhibitory
activity toward COX-2 (49.4–80.6%) over COX-1 (8.6–30.6%)
at 10 lM, while 2-sulfonamido-5-(4-methoxy)phenyl-6-(4-sul-
fonylmethyl)phenylimidazo[2,1-b][1,3,4] thiadiazole showed
IC50 values of 3.24 lM (COX-2) and >50 lM (COX-1). These
compounds also exhibited a signiﬁcant reduction in paw ede-
ma in the range of 42.32–70.09% which was comparable to
the standard drug celecoxib when administered orally at the
dose of 10 mg/kg in the carrageenan-induced rat paw edema
model.
Jadhav et al. (2008) evaluated antiinﬂammatory and anal-
gesic activities of 6-aryl-2-(6-methyl-benzofuran-3-
ylmethyl)imidazo[2,1-b][1,3,4]thiadiazoles 34 and their 5-carb-
aldehyde/(morpholin-4-yl)methyl derivatives. The 5-carbalde-
hyde substitution showed enhanced antiinﬂammatory and
analgesic activity.
N
S
N
N
R
O
R= Br, Cl, NO2
34
Mazzone et al. (1984) studied analgesic, antipyretic and
antiphlogistic activities of 2,6-diaryl-imidazo[2,1-b][1,3,4]
thiadiazoles 5 and reported to exhibit peripheral analgesic
activity. Some of these compounds showed signiﬁcant
activity compared to indomethacin as standard drug
(p< 0.05).
Ram et al., (1996) reported insigniﬁcant antiinﬂammatory
activity of 2-(3-(4-methylphenyl)-1H-pyrazol-5-ylmethyl)-imi-
dazo[2,1-b][1,3,4]thiadiazole 35.
N
S
N
N
35
N
NH
Cl
S470 B.A. Bhongade et al.3.5. Carbonic anhydrase inhibition and diuretic activity
Cerebrovasodilation effects of 6-(hetero)arylimidazo
[2,1-b][1,3,4]thiadiazole-2-sulfonamides 31 and some of their
5-methyl/phenyl analogs through selective inhibition of the en-
zyme carbonic anhydrase was studied (Barnish et al., 1980).
The in vitro carbonic anhydrase inhibitory activity of 6-phe-
nyl/(4-hydroxy)phenyl/tert-butyl derivatives were comparable
to acatazolamide and methazolamide standard drugs. 6-tert-
Butylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide was re-
ported to increase selectively cerebral blood ﬂow in animals
without producing high levels of metabolic acidosis. This
compound was found to increase vertebral blood ﬂow in
conscious beagle dogs by a maximum of 39 ± 7% (iv,
2.5 mg/kg), 31 ± 9% (oral, 2.5 mg/kg) and 49 ± 12% (oral,
5 mg/kg). However, this compound was reported to be
about ﬁve times more effective than the standard 4-[(4-meth-
oxypiperidino)sulfonyl]-2-chlorobenzenesulfonamide, while 6-
admantanyl/methyl/tert-butyl derivatives exhibited diuretic
ED50 values of 5–6 mg/kg for urine output after oral
administration.
The effect of uricosuric drug candidate, 3-(2-diethylamino-
methyl-6-phenylimidazo[2,1-b][1,3,4]thiadiazole-5-yl)-1-piperi-
din-1-yl-propenone 36 (BAY r4420) on kidney rat function
demonstrated the increase in glomerular ﬁltration rate as the
major cause of diuretic action, while the uricosuric action
was due to impairment of urate reabsorption in the later part
of proximal tubule (Sigrist et al., 1987). These studies resulted
in the lead molecules for the development of new series of
diuretic drug candidates.
N
S
N
N
(C2H5)2NH2C
O
N
36
Andreani et al., (1994a) have reported higher diuretic activ-
ity in rats for (E)-2-methyl-6-phenyl-imidazo[2,1-b][1,3,4]thia-
diazole-5-carbaldehyde dimethylamino hydrazone 37 than
reference drugs, hydrochlorothiazide and furosemide at the
dose of 2.5, 10 and 40 mg/kg.
N
S
N
N
N
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N
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3.6. Anticancer activityGadad et al. (1999) have reported anticancer activity of 5-carb-
aldehyde-6-arylimidazo[2,1-b] [1,3,4]thiadiazole-2-N-(dimeth-
ylamino)-sulfonamides 38 and 5-bromo-6-aryl/ethylacetate-
imidazo[2,1-b][1,3,4] thiadiazole-2-sulfonamides 11. Most of
these compounds showed signiﬁcant in vitro cytotoxic effects
(log10 GI50 value <4) against a panel of approximately 60
human tumor cell lines.C6H5, 
4-Br-C6H4, 
4-Cl-C6H4, 
4-NO2-C6H4, 
4-C6H5-C6H4, 
3-coumarinyl, 
5-(4-NO2-C6H4)-2-furyl
R6=
N
S
N
N
38
S
(H3C)2NHC=N
O
O
R6
H
O
Terzioglu and Gursoy (2003) have reported in vitro cyto-
toxicity studies of 2,6-dimethylindene-N0-substituted phenylm-
ethylene-imidazo[2,1-b][1,3,4]thiadiazole-5-carbohydrazide
derivatives 39 against a panel of tumor cell lines. Among these,
N0-(2-hydroxy-phenylmethylene) derivative was highly active
against ovarion cell line (OVCAR-3, log10 GI50 value 5.51),
breast cell line (MCF-7, log10GI50 value 4.51) and leukemia
cell line (KL-60, log10GI50 value 4.50).
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S N
39
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H
H
R
H; 
4-CH3C6H5; 
2-OHC6H4; 
4-CH3OC6H5;
4-BrC6H4; 
4-ClC6H4; 
4-FC6H4; 
4-NO2C6H4
R=
6-(4-Bromophenyl)imidazo[2,1-b][1,3,4]thiadiazole 40 have
reported to be inactive in vivo against AH 13 and L 1210 tu-
mors in rats and mice, respectively (Kamiya et al., 1983; Miya-
hara et al., 1982).
N
S N
Br
40
Karki et al. (2011) reported cytotoxic activity of 2-aralkyl-5-
substituted-6-(40-ﬂuorophenyl)-imidazo[2,1-b][1,3,4]thiadiazoles 41
on human T-cell leukemia cell line (CEM). Compounds with sub-
stituents (41: R=H, R5=Br; R=H, R5=CHO and R=CH3,
R5= CHO) exhibited IC50 values in the ranges of 10–16 and 8–
26 lg/mLagainstCEMcell linebasedonTrypanblueandMTTas-
say, respectively after 72 h of inhibition. These studies signify
that the tested compound did not affect cell cycle progression
however the cytotoxic activity was mediated through apoptosis.
N
S N
F
41R
R= H,Cl,F,CH3;      
R= H,Cl,F,Br,CH3;  
R= H,Cl;                 
R= H,Cl,CH3;
R5
R5= H
R5= SCN
R5= Br
R5= CHO
Biological activities of imidazo[2,1-b][1,3,4]thiadiazole derivatives: A review S471Noolvi et al. (2011) reported anti-tumor activity of a series
of 2-cyclopropylimidazo[2,1-b][1,3,4]thiadiazoles 42. Com-
pound 5-bromo-6-(4-chlorophenyl)-2-cyclopropylimidazo[2,1-
b][1,3,4]thiadiazole was reported to be the most active candi-
date of the series against leukemia K-562, colon cancer
HCT-15, melanoma SK-MEL and prostate cancer PC-3 with
GI50 1.79, 2.02, 2.17 and 2.22 mM, respectively with a degree
of selectivity toward Leukemic cancer cell line based upon
MG MID ratio (3:6).
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42
R5=
R5
R
H, 
4-Cl, 
4-Br,
4-F, 
2,4-Cl2, 
2,4-(OH)2 , 
3-NH2, 
4-NH2, 
3-NO2, 
4-NO2, 
2-OH
Br, 
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Taher et al. (2012) evaluated 2-arylimidazo[2,1-b][1,3,4]
thiadiazol-6(5H)-ones 43 and 2-phenylimidazo[2,1-b][1,3,4]
thiadiazol-5,6-diones 44 against NCI 60 cell line panel assay.
Most potent compound (43: R = H) exhibited fourfold more
broad spectrum activity than standard drug 5-ﬂuorouracil with
GI50, TGI and LC50 values of 6.0, 17.4 and 55.1 lM, respec-
tively.
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Recently, Kaur et al. (2012) and Noolvi et al. (2012) re-
ported in vitro anticancer activity of 2,6-disubstituted imi-
dazo[2,1-b][1,3,4]thiadiazoles 27 and 45 on NCI human
tumor cell lines. Compound (45: R2 = 4-CH3O–C6H4;
R6 = 3-NH2–C6H5) showed GI50 of 0.114 and 0.743 lM
against HOP-92 (non small cell lung) and CAKI-1 (renal) can-
cer cell lines, respectively.
N
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45
R2=
R2 R6
R6= C6H5,
2,4-(OH)2-C6H3,
3-NH2-C6H4,
4-OCH3-C6H4,
4-NH2-C6H4
4-CH3O-C6H4 R2=
R6= 2,4
-(OH)2-C6H3,
3-NH2-C6H4,
2-Cl,5-NO2-C6H3
3.7. Anthelmintic and antiamebic activity
Marin et al. (1992) evaluated (2-amino/alkyl/arylimidazo
[2,1-b][1,3,4]thiadiazol-6-yl)carbamic acid methyl esters 46
and 2-substituted-6-phenyl-imidazo[2,1-b][1,3,4]thiadiazoles
47 for their in vitro anthelmintic activity against the free-livingnematode Caernorhabditis elegans, eggs of Heligmosomoides
polygyrus and in vivo activity against Aspicularis tertaptera,
Syphacia obvelata, Strongyloides ratti and Hymenoleptis nama
in mice. Some of the derivatives were found to exhibit
equipotent activity compared to standard drug mebendazole
in vitro while they were inactive in vivo. 2-Carbamic acid
methyl ester-phenyl and 2-butyl-6-carbamic acid methyl ester
derivatives exhibited 99% (MEC= 2.5 lg/mL) and 98%
(MEC= 25 lg/mL) inhibition against Caernorhabditis elegans
while, 2-propylsulfanylimidazo[2,1-b][1,3,4]thiadiazole-6-yl)
carbamic acid methyl ester showed a minimum ovicidal con-
centration of 0.5 lg/mL against Heligmosomoides polygyrus.
However, other studies have shown insigniﬁcant activity com-
pared to niclosamide as standard drug against Hymenoleptis
nama and Strongyloides ratti infections in mice and
Caenorhabditis elegans for these compounds (47: R2 = H,
CH3, C2H5) (Alonso et al., 1986; Pumarola et al., 1987;
Cativiela et al., 1989).
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Andotra et al. (1993) screened 2-aryl-6-(4-bromo-phenyl)-
imidazo[2,1-b][1,3,4]thiadiazoles 48 and their 5-bromo/nitro
derivatives for antiamebic activity.
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Br
R5
R5=
2,4-(OMe)2,5-Et-C6H2,
2-OEt-4-OMe-5-Et-C6H2,
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2-OMe-4-OEt-5-nPr-C6H2,
2-NO2-4,5(-O-CH2-O-)C6H2
H, Br, NO2;
R2=
3.8. Leishmanicidal activity
Leishmanicidal activity of 2-benzylsulfanyl-6-(4-chloro-phe-
nyl)-imidazo[2,1-b][1,3,4]thiadiazoles 49 with less than 30%
inhibition against L. Donovani (Ram and Haque, 1996)
was reported as compared to standard drug sodium
stibogluconate. Similarly, 2-[ethyl(imidazolidine-2-ylide)ace-
tate]-6-(4-chloro/bromo-phenyl)-imidazo[2,1-b][1,3,4]thiadiaz-
oles exhibited 31–40% inhibition against L. donovani (Jag,
1999).
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S472 B.A. Bhongade et al.3.9. Calcium channel blocking and local anesthetic activity
Sanﬁlippo et al. (1988) studied calcium channel blocking and
local anesthetic activity of 6-[4-(dibutylamino)propoxy]ben-
zoyl-2-methylimidazo[2,1-b][1,3,4]thiadiazole 50. This com-
pound demonstrated 82% inhibition of Ca2+ dependent
inhibition of smooth muscle contraction at 10 lM comparable
to standard bepridil (81%). In the nitrendipine binding assay
compound 50 exhibited an IC50 value of 1.1 lM, whereas it
was devoid of local anesthetic activity in the mouse horizontal
screen test.
50
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Bu3.10. Other biological activities
Andreani et al., (1994b) studied the cardiotonic activity of
some 2-methylimidazo[2,1-b][1,3,4]thiadiazoles 51 by measur-
ing positive inotrophic activity on the guinea pig atria. Among
them 6-pyridyl analogs were signiﬁcantly active compared to
the standard drug, sulmazole.
N
S
N
N
R6
51
R6= 3-C5H4N, 
4-C5H4N, 
2,5-(OCH3)2C6H3
Ohta et al. (1994) have studied the herbicidal activity of
1-(6-methyl-imidazo[2,1-b][1,3,4]thiadiazole-6-yl)-sulfonyl-3-
(4,6-dimethoxypyrimidin-2-yl)urea 52.
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Andreani et al. (2000) have reported signiﬁcant antisecre-
tory activity of 2,6-dimethyl-5-hydroxymethylimidazo[2,1-
b][1,3,4]thiadiazole in the isolated rabbit gastric gland assay.
Salehi et al. (2006) have reported 6-phenylimidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamides as the inhibitors of
Jun kinase (JNK) activation and apoptosis by a mechanism
involving induced production of HSP70. Conroy et al. (1984)
have studied the rates of reaction for the nonenzymatic
conjugation of reduced glutathione (GSH) and L-cysteine of
the compound 6-tert-butylimidazo[2,1-b][1,3,4]thiadiazole-
2-sulfonamide. The pseudo-ﬁrst order rate constants of
9.9 ± 1.2 and 9.6 ± 1.0 · 103 min1 were observed for
GSH and L-cysteine, respectively. The compound was also
inactivated by nucleophilic displacement of sulfamoyl group
by thiolate anions at pH 7.5 via the SN2 addition–elimination
process.3.11. Toxicity studies
Khazi et al. (1996) evaluated acute toxicity of some 6-
(hetero)arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamides
32. The compounds (32: R6 = biphenyl; 3-coumarinly; 5-ni-
tro-2-thenly) and (32: R6 = 4-nitrophenyl; R5 = bromo,
R6 = 3-coumarinyl) exhibited an LD50 of 1780 and more than
2830 mg/kg b.w. reﬂecting their low toxicity.
4. Conclusions
The synthetic and biological research in the ﬁeld of imi-
dazo[2,1-b][1,3,4]thiadiazole heterocycles has resulted in some
therapeutically potential analogs. However, to the best of
our knowledge, presently none of the drugs is currently
available in the market or undergoing clinical trials. However,
early synthetic efforts were attributed to the development of
uricosuric drug candidate, potent diuretic and anticonvulsant
agent.
The derivatives of imidazo[2,1-b][1,3,4]thiadiazoles contain-
ing sulfonamide group exhibited interesting biological activities
and emerged as potential leads for the further development as
drug candidates. The research efforts during the last decade is
focused mainly on the synthesis and evaluation of imi-
dazo[2,1-b][1,3,4]thiadiazole derivatives as antibacterial,
antiTB and anticancer agents. In general the nature and type
of substituents at position 2- and 6- of imidazo[2,1-
b][1,3,4]thiadiazole nucleus showed a marked inﬂuence on the
spectrum and potency of biological activities. Thus, further sys-
tematic structure–activity studies may provide insights into the
development of more potent derivatives as drug candidates.
So far, the major developments in the ﬁelds of chemistry
and biology of imidazo[2,1-b][1,3,4]thiadiazole have been fol-
lowing the traditional organic synthetic strategies. The biolog-
ical evaluation at the molecular and enzymatic levels, use of
molecular modeling and computational tools in order to
understand the molecular requirements are among the rela-
tively ignored areas of research in this class of chemical com-
pounds. In conclusion, traditional synthetic efforts led to
some potential lead molecules, however rational drug design
techniques may accelerate drug discovery in the chemical class
of imidazo[2,1-b][1,3,4]thiadiazoles in future.
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